The value of PET/CT radiomics for predicting survival outcomes in patients with pancreatic ductal adenocarcinoma

Sci Rep. 2024 Nov 22;14(1):28958. doi: 10.1038/s41598-024-77022-4.

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is associated with poor prognosis even without distant metastases, necessitating in-depth characterization of primary tumors for survival prediction. We assessed the feasibility of using FDG-PET/CT radiomics to predict overall survival (OS) in PDAC. This retrospective study included PDAC patients without distant metastasis who underwent FDG-PET/CT for initial staging. Primary tumors were segmented from FDG-PET/CT images, extracting 222 radiomics features. A radiomics-based risk score (Rad-score) was developed using Cox proportional hazards regression with LASSO to predict OS. The prognostic performance of the Rad-score was compared with a clinical model (demographics, disease stage, laboratory results) using Harrell's concordance index (C-index) and bootstrapping. 140 patients were included, with a mortality rate was 72.9% during follow-up (total population, 19.5 ± 19.2 months; survivors, 34.4 ± 28.8 months). Eleven radiomics features were significant for survival prediction. The Rad-score predicted OS with a C-index of 0.681 [95% CI, 0.632-0.731]. A model integrating clinical parameters and Rad-score outperformed the clinical-only model in predicting OS (C-index 0.740 [0.715-0.816] vs. 0.673 [0.650-0.766]; C-index difference 0.067 [0.014-0.113]; P < 0.001). These findings suggest that incorporating FDG-PET/CT radiomics into preexisting prognotic stratification paradiagm may enhance survival prediction in PDAC, warranting large-scale studies to confirm its applicability in clinical practice.

Keywords: FDG-PET/CT; Pancreas cancer; Radiomics; Survival.

MeSH terms

  • Aged
  • Carcinoma, Pancreatic Ductal* / diagnostic imaging
  • Carcinoma, Pancreatic Ductal* / mortality
  • Carcinoma, Pancreatic Ductal* / pathology
  • Female
  • Fluorodeoxyglucose F18
  • Humans
  • Male
  • Middle Aged
  • Pancreatic Neoplasms* / diagnostic imaging
  • Pancreatic Neoplasms* / mortality
  • Pancreatic Neoplasms* / pathology
  • Positron Emission Tomography Computed Tomography* / methods
  • Prognosis
  • Radiomics
  • Retrospective Studies

Substances

  • Fluorodeoxyglucose F18